Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways
- PMID: 10732327
- DOI: 10.1016/s1071-5576(99)00058-1
Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways
Abstract
The intriguing biology of estrogens and progestins in their diverse target cells is determined by the structure of the hormonal ligand, the receptor subtype or isoform involved, the nature of the hormone-responsive gene promoter, and the character and balance of coactivators and corepressors that modulate the cellular response to the receptor-ligand complex. Estrogens regulate the growth, differentiation, and functioning of diverse target tissues, both within and outside of the reproductive system. Most of the actions of estrogens appear to be exerted through the estrogen receptor (ER) of target cells, an intracellular receptor that is a member of a large superfamily of proteins, which function as ligand-activated transcription factors, regulating the synthesis of specific RNAs and proteins. To understand how the ER discriminates between estrogen ligands, which activate the ER, and antiestrogen ligands, which fail to effectively activate the ER, we have generated and analyzed human ERs with mutations or other alterations in portions of the receptor. These studies provide evidence for the promoter-specific and cell-specific actions of the estrogen-occupied and antiestrogen-occupied ER, highlight a regional dissociation of the hormone-binding and transcription activation functions in domain E of the receptor, and indicate that some of the contact sites of estrogens and antiestrogens in the ER are likely different. In addition, multiple interactions among different cellular signaling pathways are involved in the regulation of gene expression and cell proliferation by the ER. In several cell types, protein kinase activators and some growth factors enhance the transcriptional activity of the ER. Cyclic AMP also alters the agonist/antagonist balance of some antiestrogens. Estrogens, and antiestrogens to a lesser extent, as well as protein kinase activators and growth factors, increase phosphorylation of the ER and possibly other proteins involved in the ER-specific response pathway, suggesting that changes in cellular phosphorylation state will be important in determining the biologic activity of the ER and the effectiveness of antiestrogens as estrogen antagonists. The ER also has important interrelationships with the progesterone receptor (PR) system in modulation of biologic responses. Liganded PR-A and PR-B can each suppress estradiol-stimulated ER activity, with the magnitude of repression dependent on the PR isoform, progestin ligand, promoter, and cell type. These findings underscore the mounting evidence for the importance of interactions between members of the steroid hormone receptor family.
Similar articles
-
Estrogen receptors: bioactivities and interactions with cell signaling pathways.Biol Reprod. 1996 Feb;54(2):287-93. doi: 10.1095/biolreprod54.2.287. Biol Reprod. 1996. PMID: 8788178 Review.
-
Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. doi: 10.1016/s0960-0760(00)00104-7. J Steroid Biochem Mol Biol. 2000. PMID: 11162936 Review.
-
Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors.Mol Cell Biol. 1995 Apr;15(4):1847-57. doi: 10.1128/MCB.15.4.1847. Mol Cell Biol. 1995. PMID: 7891678 Free PMC article.
-
Determinants for the repression of estrogen receptor transcriptional activity by ligand-occupied progestin receptors.J Steroid Biochem Mol Biol. 1997 Nov-Dec;63(4-6):175-88. doi: 10.1016/s0960-0760(97)00089-7. J Steroid Biochem Mol Biol. 1997. PMID: 9459183
-
Antiestrogens: mechanisms and actions in target cells.J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):387-93. doi: 10.1016/0960-0760(95)00084-d. J Steroid Biochem Mol Biol. 1995. PMID: 7626486
Cited by
-
Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.J Clin Invest. 2018 Oct 1;128(10):4622-4638. doi: 10.1172/JCI120583. Epub 2018 Sep 17. J Clin Invest. 2018. PMID: 30222141 Free PMC article. Clinical Trial.
-
Effective Components of Panax notoginseng-Salvia miltiorrhiza in the Treatment of Melasma and Its Experimental Study.ACS Omega. 2025 Jan 14;10(3):3033-3043. doi: 10.1021/acsomega.4c09799. eCollection 2025 Jan 28. ACS Omega. 2025. PMID: 39895736 Free PMC article.
-
A Single Administration of Progesterone during the Neonatal Period Shows No Structural Changes in Male Reproductive Tracts in Mice.Acta Histochem Cytochem. 2023 Dec 28;56(6):127-136. doi: 10.1267/ahc.23-00052. Epub 2023 Dec 23. Acta Histochem Cytochem. 2023. PMID: 38318101 Free PMC article.
-
Association of perceived tinnitus with duration of hormone replacement therapy in Korean postmenopausal women: a cross-sectional study.BMJ Open. 2017 Jul 10;7(7):e013736. doi: 10.1136/bmjopen-2016-013736. BMJ Open. 2017. PMID: 28698314 Free PMC article.
-
Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers.Front Endocrinol (Lausanne). 2023 Apr 27;14:1106520. doi: 10.3389/fendo.2023.1106520. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37181043 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials